Recent Finacing
Recent Raise
ResoTher Pharma develops RTP-026, an Annexin A1 N‑terminus analogue that stimulates FPR2 to modulate post‑myocardial infarction inflammation; completed Phase 1 and preparing Phase 2a STEMI PCI studies.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at ResoTher Pharma.
